BNC-210

BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor,[1] by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder.[2] The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials.[3]

BNC-210
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC17H23N3O3
Molar mass317.389 g·mol−1
3D model (JSmol)

It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.[4]

Phase I trials have shown no serious side effects.

Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States,[5] but in November 2014, was released back to Bionomics in a mutual agreement.[6] Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.

As of April 2015, BNC210 is in phase II clinical trials.[7] The estimated study completion date is September 2018. [2]

Study Details

The clinical trial is currently testing twice daily oral dosages of 600 mg, 300 mg, and 150 mg, for 12 weeks. [2] The primary objective of the trial is for the treatment of PTSD with a secondary objective for the effectiveness in treating anxiety disorders and depression. [2]

See also

References
  1. http://www.bionomics.com.au/upload/investors/asx-announcements/4736/ASX695%20%20BNC210%20Phase%201b%20initiation.pdf
  2. Clinicaltrials.gov. "www.clinicaltrials.gov" (HTML). Clinicaltrials.gov. Retrieved 2018-01-04.
  3. "Bionomics - Pipeline". Retrieved 2010-11-09. Bionomics has discovered a novel compound, BNC210, that offers dramatic competitive advantages over existing treatments
  4. O'Connor, S.; Andriambeloson, E.; Huyard, B.; Wagner, S.; Sleebs, B.; Quasi, N.; Bui, C.; Street, I. "BNC210: A Novel Compound with Potent Anxiolytic Activity" (PDF). Bionomics Limited. Retrieved 2010-11-09. By applying a targeted medicinal chemistry strategy beginning from a compound cited in the literature, Bionomics has developed BNC210
  5. "Archived copy". Archived from the original on 2014-05-04. Retrieved 2013-02-01.CS1 maint: archived copy as title (link)
  6. http://www.biotechdaily.com.au/media/backissues/2014/11%20Nov/BD%20Biotech%20Daily%20Nov%2011.pdf
  7. Bionomics Limited. "www.prnewswire.com" (HTML). PRNewswire. Retrieved 2015-06-10.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.